Adenocarcinoma Pancreas clinical trials

Explore recruiting adenocarcinoma pancreas clinical trials.

Recruiting adenocarcinoma pancreas studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Adenocarcinoma Pancreas trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer

Germany

Phase II and Phase III (Integrated) EU CTIS Study details

A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Using organoids to predict efficacy of adjuvant treatment to improve outcome in resectable pancreatic cancer (UNITEPANC)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu FAP 2286 in Participants with an Advanced Solid Tumor

Italy, Spain, Belgium, France

Therapeutic exploratory (Phase II) EU CTIS Study details

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Adenocarcinoma Pancreas trials by city

Adenocarcinoma Pancreas in Toronto Adenocarcinoma Pancreas in Vancouver Adenocarcinoma Pancreas in Montreal Adenocarcinoma Pancreas in Calgary Adenocarcinoma Pancreas in Edmonton Adenocarcinoma Pancreas in Ottawa Adenocarcinoma Pancreas in Winnipeg Adenocarcinoma Pancreas in Quebec City Adenocarcinoma Pancreas in Hamilton Adenocarcinoma Pancreas in Kitchener Adenocarcinoma Pancreas in London Adenocarcinoma Pancreas in Halifax Adenocarcinoma Pancreas in New York Adenocarcinoma Pancreas in Los Angeles Adenocarcinoma Pancreas in Chicago Adenocarcinoma Pancreas in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease